Ocugen Inks US Development Pact For Its Intranasal COVID-19 Vaccine

  • Ocugen Inc OCGN has entered into an exclusive license agreement with Washington University to develop, manufacture and commercialize its intranasally delivered COVID-19 vaccine in the U.S., Europe, and Japan.
  • This vaccine is already authorized for emergency use in India and is essential to Ocugen's COVID-19 vaccine portfolio.
  • Related: Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years.
  • "Washington University's COVID-19 nasal vaccine technology has been shown to induce strong mucosal immunity with the potential to reduce SARS-CoV-2 infection, transmission, and the emergence of new variants," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Ocugen's intranasal vaccine candidate is a recombinant, replication-deficient, adenovirus-vectored vaccine with a prefusion-stabilized spike protein. 
  • Ocugen intends to work closely with U.S. government agencies tasked with pandemic preparedness and response to initiate clinical trials, manufacture the intranasal vaccine, and pursue funding and investment options.
  • Price Action: OCGN shares are up 12.9% at $2.06 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!